Optimal working dilutions should be determined experimentally by the investigator. Suggested starting dilutions are as follows: WB (1:500-1:2000), IF (1:200-1:1000), IHC-P (1:100-1:300), ELISA (1:10000). Not yet tested in other applications.
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage
-20 °C
Storage Comment
Stable for one year at -20°C from date of shipment. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Aliquot to avoid repeated freezing and thawing.
Target
NFKBIA
(Nuclear Factor of kappa Light Polypeptide Gene Enhancer in B-Cells Inhibitor, alpha (NFKBIA))
IKBA antibody, MAD-3 antibody, NFKBI antibody, AI462015 antibody, Nfkbi antibody, RL/IF-1 antibody, ECI-6/IKBA antibody, NFKBIA antibody, ikbaB antibody, wu:fb81f08 antibody, zgc:56666 antibody, zgc:77616 antibody, ikbaA antibody, wu:fj16a07 antibody, zgc:85769 antibody, NFKB inhibitor alpha antibody, nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha antibody, nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha b antibody, nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha a antibody, NFKBIA antibody, Nfkbia antibody, nfkbiab antibody, nfkbiaa antibody
Background
Rabbit Anti-IκB-α (phospho Ser32/S36) Polyclonal Antibody,NFKBIA, IKBA, MAD3, NFKBI, NF-kappa-B inhibitor alpha, I-kappa-B-alpha, IkB-alpha, IkappaBalpha, Major histocompatibility complex enhancer-binding protein MAD3,NFKBIA encodes a member of the NF-kappa-B inhibitor family, which contain multiple ankrin repeat domains. NFKB inhibitor alpha interacts with REL dimers to inhibit NF-kappa-B/REL complexes which are involved in inflammatory responses. NFKB inhibitor alpha moves between the cytoplasm and the nucleus via a nuclear localization signal and CRM1-mediated nuclear export. Mutations in NFKBIA have been found in ectodermal dysplasia anhidrotic with T-cell immunodeficiency autosomal dominant disease.,NF-kappa-B inhibitor alpha